Meridian Bioscience said today that it will now directly distribute its diagnostic products in Australia through its subsidiary Bioline Australia.
Cincinnati, Ohio-based Meridian said that it is transitioning sales of its diagnostic products from its current distributor to a direct sales force through Bioline, which is headquartered in London but has branches in Sydney, Boston, and Berlin.
Meridian's portfolio of infectious disease diagnostic products includes both traditional immunoassays and the company's newer molecular platform, Illumigene, which uses loop-mediated isothermal amplification technology, and will be the primary product offering through Bioline. Currently, Meridian offers only an Illumigene test for C. difficile, but is also developing a test for Group B Streptococcus.
Meridian acquired Bioline in July 2010 for $23.3 million in a bid to expand both its PCR and molecular diagnostics plays (PCR Insider 7/22/10).
"Combining our Australian business through Bioline/Meridian was a strategic decision toward strengthening our global distribution," Richard Eberly, chief commercial officer of Meridian, said in a statement.
Meridian had previously inked an exclusive distribution agreement in Australia in 2009 with Immuno Pty.